{'fraction_non_alphanumeric': 0.019860973187686197, 'fraction_numerical': 0.0009930486593843098, 'mean_word_length': 5.76510067114094, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New forms of treatment for inflammatory bowel disease.

Until the aetiology of inflammatory bowel disease is established the development of new forms of treatment is limited. Induction of remission is associated with inhibition or a decrease in the formation of the inflammatory mediators or, altematively, may be achieved by blocking their specific receptors. Prostanoids, leukotrienes, platelet activating factor, cytokines, and free oxygen radicals may all contribute to the pathogenesis of the inflammatory response. The drugs that effectively modulate the disease process such as steroids, sulphasalazine, and 5-aminosalicylic acid affect most or all of the inflammatory mediators. Current efforts, however, are directed to the development of new drugs with selective inhibition or receptor blockade of a single mediator. In addition, new therapeutic aproaches include manipulation of eicosanoid formation by dietary fatty acids, development of topically active new steroid components, and the blockade